213 related articles for article (PubMed ID: 14633703)
1. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Xu W; Yuan X; Jung YJ; Yang Y; Basso A; Rosen N; Chung EJ; Trepel J; Neckers L
Cancer Res; 2003 Nov; 63(22):7777-84. PubMed ID: 14633703
[TBL] [Abstract][Full Text] [Related]
2. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
Lenferink AE; Busse D; Flanagan WM; Yakes FM; Arteaga CL
Cancer Res; 2001 Sep; 61(17):6583-91. PubMed ID: 11522658
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
Srethapakdi M; Liu F; Tavorath R; Rosen N
Cancer Res; 2000 Jul; 60(14):3940-6. PubMed ID: 10919672
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
5. Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.
Bonvini P; An WG; Rosolen A; Nguyen P; Trepel J; Garcia de Herreros A; Dunach M; Neckers LM
Cancer Res; 2001 Feb; 61(4):1671-7. PubMed ID: 11245482
[TBL] [Abstract][Full Text] [Related]
6. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Moasser MM; Basso A; Averbuch SD; Rosen N
Cancer Res; 2001 Oct; 61(19):7184-8. PubMed ID: 11585753
[TBL] [Abstract][Full Text] [Related]
7. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.
Basso AD; Solit DB; Munster PN; Rosen N
Oncogene; 2002 Feb; 21(8):1159-66. PubMed ID: 11850835
[TBL] [Abstract][Full Text] [Related]
8. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.
Lim SJ; Lopez-Berestein G; Hung MC; Lupu R; Tari AM
Oncogene; 2000 Dec; 19(54):6271-6. PubMed ID: 11175341
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis.
Hostein I; Robertson D; DiStefano F; Workman P; Clarke PA
Cancer Res; 2001 May; 61(10):4003-9. PubMed ID: 11358818
[TBL] [Abstract][Full Text] [Related]
10. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells.
Neve RM; Sutterlüty H; Pullen N; Lane HA; Daly JM; Krek W; Hynes NE
Oncogene; 2000 Mar; 19(13):1647-56. PubMed ID: 10763821
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Cuello M; Ettenberg SA; Clark AS; Keane MM; Posner RH; Nau MM; Dennis PA; Lipkowitz S
Cancer Res; 2001 Jun; 61(12):4892-900. PubMed ID: 11406568
[TBL] [Abstract][Full Text] [Related]
12. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
Schulte TW; Neckers LM
Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
[TBL] [Abstract][Full Text] [Related]
13. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90.
Xu W; Mimnaugh E; Rosser MF; Nicchitta C; Marcu M; Yarden Y; Neckers L
J Biol Chem; 2001 Feb; 276(5):3702-8. PubMed ID: 11071886
[TBL] [Abstract][Full Text] [Related]
15. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A.
Li L; Ren CH; Tahir SA; Ren C; Thompson TC
Mol Cell Biol; 2003 Dec; 23(24):9389-404. PubMed ID: 14645548
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mineralocorticoid and glucocorticoid receptor function by the heat shock protein 90-binding agent geldanamycin.
Bamberger CM; Wald M; Bamberger AM; Schulte HM
Mol Cell Endocrinol; 1997 Aug; 131(2):233-40. PubMed ID: 9296382
[TBL] [Abstract][Full Text] [Related]
17. Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1.
Fujita N; Sato S; Ishida A; Tsuruo T
J Biol Chem; 2002 Mar; 277(12):10346-53. PubMed ID: 11779851
[TBL] [Abstract][Full Text] [Related]
18. Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions.
Jaumot M; Hancock JF
Oncogene; 2001 Jul; 20(30):3949-58. PubMed ID: 11494123
[TBL] [Abstract][Full Text] [Related]
19. Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo.
Bucci M; Roviezzo F; Cicala C; Sessa WC; Cirino G
Br J Pharmacol; 2000 Sep; 131(1):13-6. PubMed ID: 10960063
[TBL] [Abstract][Full Text] [Related]
20. Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity.
An WG; Schnur RC; Neckers L; Blagosklonny MV
Cancer Chemother Pharmacol; 1997; 40(1):60-4. PubMed ID: 9137531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
